+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07020247

Phase 3 Study of Personalized Long-Course Radiotherapy and Chemotherapy With or Without Serplulimab Immunotherapy for Locally Advanced Rectal Cancer

Led by West China Hospital · Updated on 2025-06-13

184

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatments for patients with locally advanced rectal cancer LARC who have specific risk factors and tumors located within 10 cm of the anal margin. The study aims to compare the complete response rate, defined as a combination of pathological complete response and clinical complete response lasting over one year, between two treatment approaches. This phase III, multicenter, randomized controlled study includes 184 patients to explore the potential benefits of adding immunotherapy with Serplulimab to personalized long-course radiotherapy plus chemotherapy. The study has two groups. The experimental group receives an induction phase with two cycles of CAPOX chemotherapy plus Serplulimab, followed by two cycles of the same during concurrent chemoradiotherapy, and two further cycles during consolidation chemotherapy. Radiotherapy is delivered using intensity-modulated techniques at a specified dose, with additional boost doses for some patients. The control group receives the same chemotherapy and radiotherapy schedule but without Serplulimab. Tumor response is assessed after consolidation chemotherapy to decide between surgery or watchful waiting. Participants will undergo regular assessments including imaging and clinical evaluations to monitor tumor response and safety. Researchers will measure the complete response rate at one year and secondary outcomes such as surgical success, disease-free survival, recurrence rates, overall survival, adverse effects, quality of life, and surgical safety for up to three years. The study includes monitoring of organ function, treatment adherence, and follow-up care over the study period.

CONDITIONS

Brief Title

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

Research Team

W

Wang Xin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here